Bio-Rad Shares Plunge as Research Funding Crunch Hits Margins

The life sciences equipment manufacturer saw its stock price slide 10.6% to $261.43 during Friday trading, extending a 14% decline over the past year. The sell-off follows a difficult fiscal period characterized by what Chief Executive Norman Schwartz described as a challenging year in 2025, defined by geopolitical instability and a tightening environment for academic grants.

Erosion of Profit Margins

The company’s profitability took a visible hit as gross margins contracted to 49.8% in the fourth quarter, down from 51.2% in the prior year. This margin compression led to adjusted earnings per share of $2.51, falling 20 cents short of Wall Street consensus estimates. According to Schwartz, both gross and operating performances failed to meet internal projections as the company struggled to navigate the shifting economic landscape.

The downturn was particularly pronounced in the company’s core life sciences segment, which reported a 2.6% decline in sales. This slump was driven by several factors currently impacting the broader industry:

• Constrained venture capital and biotech funding.
• Stagnating budgets within academic research institutions.
• Persistent geopolitical uncertainty affecting global operations.

While Bio-Rad has historically relied on steady demand from the scientific community, the current pullback in funding suggests a more cautious spending environment. The company remains under pressure to stabilize its margins as it addresses these macroeconomic headwinds and fluctuating demand for its laboratory products.